FDA Approves Regeneron and Sanofi's Dupixent for Eczema
March 28 2017 - 12:26PM
Dow Jones News
By Joseph Walker
Regeneron Pharmaceuticals Inc. and Sanofi S.A. said they will
charge $37,000 annually in the U.S. for their newly approved eczema
drug, a price the companies said they reached after months of
negotiations with pharmacy benefit managers.
The Food and Drug Administration approved the drug, called
Dupixent, for U.S. sale on Tuesday.
Through their negotiations, the companies said they aimed to set
a price the pharmacy benefit managers, or PBMs, would find
acceptable. PBMs administer prescription drug benefits for
employers and insurers.
In exchange, the companies sought, and in some cases received,
assurances that the PBMs wouldn't implement coverage restrictions
that could prevent patients from getting the drug, Regeneron CEO
Leonard Schleifer said in an interview.
Dupixent will be one of the most closely watched drug launches
this year, with analysts projecting it could reach $3.13 billion in
global annual sales in 2020 if it gains favorable insurance
coverage, according to analysts polled by FactSet.
--Denise Roland contributed to this article.
(END) Dow Jones Newswires
March 28, 2017 12:11 ET (16:11 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024